ReviewCanadian family physician Medecin de famille canadien2011
Practical use of the Framingham risk score in primary prevention: Canadian perspective.
Review in Canadian family physician Medecin de famille canadien, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06305195 (Potential Correlation Between Heart Rate Variability With Cardiovascular Risk at Different Stages of Metabolic Syndrome), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Correlation Between Heart Rate Variability With Cardiovascular Risk at Different Stages of Metabolic Syndrome: Impact of Some Antidiabetic Drugs
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Development of a high-performing, cost-effective and inclusive Afrocentric predictive model for stroke: a meta-analysis approach.BMC neurology · 2025Pooled it
- Organization of Community Mental Health Services for Persons with a Severe Mental Illness and Comorbid Somatic Conditions: A Systematic Review on Somatic Outcomes and Health Related Quality of Life.International journal of environmental research and public health · 2021Pooled it
- Association of Subjective and Objective Sleep Duration as well as Sleep Quality with Non-Invasive Markers of Sub-Clinical Cardiovascular Disease (CVD): A Systematic Review.Journal of atherosclerosis and thrombosis · 2017Pooled it
- Integrative transcriptomic and machine learning approach reveals key DDR genes and predictors of ami risk in the Bangladeshi population.Scientific reports · 2026Article
- From Misperception to Prevention: Improving Cardiovascular Health and Risk Perception Through Risk Communication in Hungary.Healthcare (Basel, Switzerland) · 2026Article
- Development and application of a scoring and visualization approach for 24-hour movement behaviours: an example based on social-emotional development in early years children.The international journal of behavioral nutrition and physical activity · 2026Article
- Predictors of atherosclerosis and dyslipidaemia among patients with thyroid disease: a cross-sectional analysis.Frontiers in endocrinology · 2026Observational
- Cost-efficient and Accurate Risk Assessment Instruments in Type 2 Diabetics with Greatest Risk for Cardiovascular Disease.Cardiology and cardiovascular medicine · 2026Article
- Evaluation of Cardiovascular Disease Risk According to the Morningness-Eveningness Status in Adult Individuals.Cureus · 2025Article
- Article
- High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).Dermatology and therapy · 2025Article
- Article
- Association of Cardiovascular Risk Factors With Major and Minor Electrocardiographic Abnormalities: A Report From the Cross-Sectional Phase of Tehran Cohort Study.Health science reports · 2025Article
- Lipidomic-Based Algorithms Can Enhance Prediction of Obstructive Coronary Artery Disease.Journal of proteome research · 2024Article
- Cardiovascular risk factors among older persons with cognitive frailty in middle income country.World journal of clinical cases · 2024Article
- Associations of dietary iron intake with cardiovascular disease risk and dyslipidemia among Chinese adults.Lipids in health and disease · 2024Article
- Greater subjective cognitive decline severity is associated with worse memory performance and lower entorhinal cerebral blood flow in healthy older adults.Journal of the International Neuropsychological Society : JINS · 2024Article
- Best-Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Smartwatches in healthcare medicine: assistance and monitoring; a scoping review.BMC medical informatics and decision making · 2023Article
- Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study.Journal of translational medicine · 2023Article
Corrections and comments
- Commented on byPuzzling result.2011
- Commented on byReliable tool.2011
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review the 2009 Canadian Cardiovascular Society guidelines and provide practical recommendations for physicians. SOURCES OF INFORMATION: Initial review of the references provided with the guidelines led to a search of the PubMed, ACP Journal Club, and Cochrane databases using the key words primary prevention and statin for English language clinical trials, randomized controlled trials, meta-analyses, and reviews conducted with human participants. References from appropriate retrieved articles were also reviewed. MAIN MESSAGE: The guidelines outline low-density lipoprotein cholesterol (LDL-C) thresholds and targets to inform optimal use of statins in the primary prevention of cardiovascular disease (CVD). Family history of CVD and levels of high-sensitivity C-reactive protein (hsCRP) are risk modifiers in calculating the risk score with the new recommendations. An electronic calculator has been developed to facilitate increased uptake of these guidelines. Large numbers of asymptomatic people, particularly the elderly, will become eligible for statin therapy according to these new guidelines. Poor uptake by physicians and patients might result from the need for repeated testing of hsCRP and LDL-C levels in people who do not perceive themselves to be ill. Controversy persists concerning the role of hsCRP in the reclassification of CVD risk, and the concept of treating LDL-C to target has never been tested as an independent variable in a randomized trial. As two-thirds of the LDL-C lowering achieved by a statin occurs at the initial dose, it might be possible to achieve considerable CVD risk reduction for those at risk by treating initially with a mid-dose statin without LDL-C follow-up.
conclusionA simplified approach might appeal to patients or physicians who find current guidelines too complex, cumbersome, or costly. Success in getting high-risk patients to take statins is key to achieving improved CVD mortality reduction.
Indexed as
Identifiers
21626897PMC3076470W2114234310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.